PubMed Health⌕ Search

Biomedical subjects

L Zanaboni

Publications and source records attributed to L Zanaboni.

7 recordsLinked to original sources
PubMed1983

[Serum lipoproteins and coronary disease in diabetes. Changes in the lipoprotein pattern in relation to the type of antidiabetic therapy].

One hundred and fifty seven maturity-onset diabetics (77 males and 80 females) with coronary heart disease (CHD) were compared with 130 non-CHD diabetic patients (62 males and 68 females) of the same age-range. Integrated mean blood pressure, duration of diabetes, serum triglycerides, beta and prebeta-lipoproteins were significantly higher and alpha lipoproteins significantly lower in CHD than in non-CHD patients. Alpha lipoproteins, duration of diabetes and beta lipoproteins were the variables of highest weight in discriminating CHD from non-CHD patients. Alpha lipoprotein had a greater discriminating power than beta lipoprotein in man, while in women the opposite occurred. In patients on insulin and on sulfonylurea therapy, both with and without CHD, the concentration of alpha lipoproteins, but not of other lipoproteins, was higher than in the corresponding subgroups of the diet-treated patients. However, within each treatment group, patients with CHD had lower alpha lipoproteins.

Blood Pressure↗
PubMed1981

Increase in lipolysis and decrease in plasma-heparin lipoprotein lipase activity and alpha 1 lipoprotein level after aminophylline in man.

Intravenous aminophylline 0.48 g produced a sharp increase in plasma free fatty acids. After three days of treatment with aminophylline 0.96 g/day i.v., plasma post-heparin lipoprotein lipase was significantly reduced, and post-heparin hepatic triglyceridase remained unchanged. alpha 1 lipoprotein was reduced by treatment, in parallel with lipoprotein lipase, while other lipoprotein fractions, serum cholesterol and triglycerides were unaffected.

Adult↗
PubMed1981

Influence of two non-steroidal anti-inflammatory drugs on lipolysis and on plasma post-heparin lipoprotein lipase activity in normal man.

Indomethacin 50 mg i.v. or p.o. and diclofenac sodium 50 mg p.o. produced a prompt and significant increase in plasma free fatty acid concentration. In 10 subjects who took indomethacin 150 mg/d p.o. for 3 days, plasma post-heparin lipoprotein lipase activity was also significantly increased. The same effect occurred in 9 subjects treated for 3 days with diclofenac sodium 50 mg t.d.s. Since both indomethacin and diclofenac sodium are potent inhibitors of prostaglandin synthetase, these findings are consistent with the hypothesis tht prostaglandins are involved in the feed-back regulation of lipolysis, and mediate the inhibitory effect of lipolysis on lipoprotein lipase activity.

Adult↗
PubMed1981

Effects of acetylsalicylic acid on plasma lipids and on post-heparin lipase activities.

Acetylsalicylic acid (ASA) was administered orally at the dose of 3 g a day for 2 days to healthy subjects. Plasma free fatty acids, serum triglycerides and prebetalipoproteins were significantly decreased, while cholesterol, beta and alpha 1 lipoproteins did not change. The two fractions (protamine-resistant and protamine-inactivated) of plasma post-heparin lipoprotein lipase activity (PHLA) significantly fell after ASA. PHLA diminution was reproduced by direct addition of ASA or sodium salicylate or of plasma from individuals under treatment with ASA to post-heparin plasma of untreated subjects and is, therefore, explained by a direct inactivation. The inhibition of PHLA was not followed by a significant impairment of the removal of circulating triglycerides.

Adult↗
PubMed1980

Evidence of an effect of inhaled disodium cromoglycate on lipid metabolism in man: enhanced lipolysis and decreased plasma post-heparin lipase activities.

Inhalation of therapeutic doses of disodium cromoglycate (DSCG) was followed by a prompt increase of plasma free fatty acids (FFA). After treatment with DSCG for 3 days both hepatic and non-hepatic (lipoprotein lipase sensu strictiori) plasma post-heparin lipoprotein lipase activities were significantly depressed. No significant change was induced on serum lipids and lipoproteins, nor on the fat tolerance curve, though a trend to an elevation of this last parameter was noted. Our results show that the inhalation of DSCG produces systemic metabolic effects, being in accord with the view that this drug raises intracellular cyclic adenosine monophosphate. Furthermore, they support the contention that lipoprotein lipase activity is controlled by intracellular concentration of FFA and/or cyclic adenosine monophosphate.

Adipose Tissue↗
PubMedDate not supplied

Serum lipoproteins in diabetes: relation of alpha-lipoprotein level to therapy.

Three hundred and sixty diabetic patients (125 on insulin, 109 on sulfonylureas and 126 on diet alone) were selected to investigate the effect of the type of treatment and of the degree of metabolic control on serum lipoproteins. Prebeta-lipoprotein concentration was higher than normal in all treatment groups. Beta-lipoproteins were significantly higher in diabetic women than in controls. No difference in beta- and prebeta-lipoprotein concentration existed between the 3 treatment groups. Alpha-lipoproteins were significantly higher in insulin-treated than in diet-treated patients irrespective of the degree of metabolic control. The daily dose of insulin and, in patients on diet or sulfonylureas, serum IRI were positively correlated to alpha-lipoprotein concentration while this lipoprotein fraction was not significantly correlated to fasting blood sugar. Alpha-lipoprotein concentration, then, appears to be markedly influenced by exogenous and endogenous insulin, independently of the degree of metabolic control.

Adult↗